Published in Alzheimers Res Ther on November 29, 2013
Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility. Mol Neurodegener (2015) 1.40
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β. Brain (2015) 1.04
APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem (2015) 0.96
The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience (2015) 0.89
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome? J Parkinsons Dis Alzheimers Dis (2014) 0.84
Gly25-Ser26 amyloid β-protein structural isomorphs produce distinct Aβ42 conformational dynamics and assembly characteristics. J Mol Biol (2014) 0.83
Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. Br J Clin Pharmacol (2016) 0.80
Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation. ACS Chem Neurosci (2015) 0.80
Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease. Prion (2016) 0.80
Amyloid β Oligomeric Species Present in the Lag Phase of Amyloid Formation. PLoS One (2015) 0.79
Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic Aβ Oligomers in Cells. Front Aging Neurosci (2016) 0.78
Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. J Mol Psychiatry (2016) 0.76
Mechanism of C-Terminal Fragments of Amyloid β-Protein as Aβ Inhibitors: Do C-Terminal Interactions Play a Key Role in Their Inhibitory Activity? J Phys Chem B (2015) 0.76
Caspase Cleaved Tau in Alzheimer's Disease: A Therapeutic Target Realized. Int J Neurol Neurother (2015) 0.75
Shear-Induced Amyloid Formation in the Brain: I. Potential Vascular and Parenchymal Processes. J Alzheimers Dis (2016) 0.75
Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Front Neurol (2017) 0.75
Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function. Sci Rep (2015) 0.75
Systematic Moiety Variations of Ultrashort Peptides Produce Profound Effects on Self-Assembly, Nanostructure Formation, Hydrogelation, and Phase Transition. Sci Rep (2017) 0.75
Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin (2017) 0.75
Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. Alzheimers Res Ther (2017) 0.75
Using chirality to probe the conformational dynamics and assembly of intrinsically disordered amyloid proteins. Sci Rep (2017) 0.75
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins (2000) 7.61
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry (1996) 6.47
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (2002) 5.32
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci (2001) 5.29
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci (2012) 4.92
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem (2002) 4.20
Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A (2005) 3.91
Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem (2009) 3.66
Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A (2010) 3.50
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A (2005) 3.48
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem (2009) 3.45
Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med (2013) 3.25
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
Atomic view of a toxic amyloid small oligomer. Science (2012) 3.13
Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging (2004) 3.13
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A (2009) 3.06
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem (2008) 2.90
Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A (2013) 2.89
Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc (2004) 2.79
Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol (2007) 2.75
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci (2004) 2.64
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev (2010) 2.64
Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A (2003) 2.33
A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol (2008) 2.32
Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem (2003) 2.31
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J (2010) 2.26
Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A (2009) 2.14
In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci U S A (2004) 2.13
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry (2006) 1.96
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J (2010) 1.91
Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J Biol Chem (1994) 1.88
Neurotoxic protein oligomers--what you see is not always what you get. Amyloid (2005) 1.84
Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol (2003) 1.81
Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci (2011) 1.79
Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem Res (2004) 1.75
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
Molecular dynamics simulation of amyloid beta dimer formation. Biophys J (2004) 1.63
Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. J Mol Biol (2008) 1.62
Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem (2002) 1.61
A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. J Am Chem Soc (2003) 1.55
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci (2009) 1.54
The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging (2005) 1.53
Mechanism for the alpha-helix to beta-hairpin transition. Proteins (2003) 1.51
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. J Mol Biol (1996) 1.45
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol (2012) 1.44
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Amyloid peptide channels. J Membr Biol (2004) 1.43
Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships. Chem Biol (2012) 1.41
Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. J Biol Chem (2002) 1.39
Elucidation of amyloid beta-protein oligomerization mechanisms: discrete molecular dynamics study. J Am Chem Soc (2010) 1.38
Properties of native brain α-synuclein. Nature (2013) 1.37
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci (2009) 1.36
The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. J Mol Biol (2009) 1.35
Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging (2010) 1.32
Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red. J Neurosci Res (1999) 1.27
Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res (2011) 1.26
Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. Mt Sinai J Med (2010) 1.26
Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med (2004) 1.24
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22
β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med (2012) 1.20
Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol (2005) 1.19
Size-dependent neurotoxicity of beta-amyloid oligomers. Arch Biochem Biophys (2010) 1.17
Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res (2005) 1.16
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging (2010) 1.14
Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging (2011) 1.09
Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Proc Natl Acad Sci U S A (1997) 1.08
Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity. J Biol Chem (2010) 1.07
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Spontaneous in vitro formation of supramolecular beta-amyloid structures, "betaamy balls", by beta-amyloid 1-40 peptide. Biochemistry (2001) 1.06
Familial Alzheimer's disease mutations differentially alter amyloid β-protein oligomerization. ACS Chem Neurosci (2012) 1.05
Discrete molecular dynamics simulations of peptide aggregation. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 1.04